RCH-01
RCH-01 is in Phase 2 for androgenetic alopecia, developed by RepliCel Life Sciences.
An autologous dermal sheath cup cell therapy whose Asian licence with Shiseido RepliCel terminated in 2021, and which has produced little public news since.
This programme is no longer being actively pursued.
- Developed by
- RepliCel Life Sciences
- Current phase
- Phase 2
- Mechanism
- Stem cell activation
- Partners
- Shiseido
- Indications
- Androgenetic alopecia
- Also known as
- RCH01, Replicel RCH-01, TS001-2009, human autologous hair follicle cells, autologous hair follicle cells
- Last public activity
- March 2017
- Copy last reviewed
- September 2026
- Record confidence
- Medium
Tests whether it works, at what dose, in a few hundred people.
Uses stem or progenitor cells to regenerate or replace follicle tissue.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Development history
- Phase 1/2
First Phase 1/2 trial on record: NCT01286649 — Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia
TrichoScience Innovations, Inc. · n=19 · December 2010
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia (TS001-2009) — ClinicalTrials.gov
- RepliCel Terminates License Agreement with Shiseido — Company release, December 2021
- RepliCel reports 60-month follow-up of the RCH-01 Phase 1 trial (TS001-2009) — Company release, March 2017
Related programmes
Other programmes in the register with the same mechanism: Stem cell activation.
- Epibiotech dermal papilla cell therapyPhase 1/2Epibiotech
- ET-02Phase 1Eirion Therapeutics
- HairClone follicle banking & cell therapyPhase 1HairClone
- OrganTech / Tsuji follicular primordiumPreclinicalOrganTech
- TissUse Smart Hair TransplantPreclinicalTissUse
- Aderans dermal sheath cup cells (Ji Gami)DiscontinuedAderans Research Institute
Cite this page
Hair Pipeline, "RCH-01 — development record", hairpipeline.com/pipeline/rch-01